INTRODUCTION
Combination antiretroviral therapy (ART) has resulted in dramatic reductions in HIV-associated morbidity and mortality for persons with access to treatment. Preferred initial ART regimens have changed over time based largely on evidence from randomized controlled clinical trials (RCTs). However, clinical trials are usually powered to detect between regimen differences in short-term suppression of plasma HIV RNA. Due to the rarity, in recent years, of clinical events such as incident AIDS-defining events and death , clinical trials [1] [2] [3] are typically underpowered to detect differences in these clinical outcome measures.
Collaborations of observational cohort studies, a complementary study design to RCTs, may have the statistical power to evaluate between-regimen differences in clinical outcomes. However, results from such studies are likely to be affected by confounding because of the non-randomized selection of initial ART regimens in clinical practice , often referred to as confounding by indication . Statistical [4] " [5] " methods can adjust for measured imbalances between treatment groups, but unmeasured confounding can never be fully excluded . [6] Recognizing these limitations, observational HIV cohort studies can play an important role in providing evidence that is not available from RCTs , . [7 8] Previous observational studies have evaluated between-regimen differences in short-term virologic failure in treatment-na ve patients ï initiating ART in clinical practice settings, often yielding findings consistent with RCT results . However, these studies have largely [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] been underpowered to evaluate between-regimen differences in clinical outcomes. Previously, the ART Cohort Collaboration (ART-CC) evaluated between-regimen differences in virologic and clinical outcomes in patients initiating ART between 1996 2002 . However,
- [22] several regimens evaluated in that study are no longer widely used in clinical practice. Furthermore, ritonavir-boosted (RTV) protease inhibitors (PIs) (amprenavir, lopinavir, saquinavir, and indinavir) were evaluated together due to the low number of such regimens in the database at the time of the study. Heterogeneity of outcomes between boosted-PI regimens may have affected the overall findings for these regimens, which were found to be inferior for both virologic and clinical outcomes, relative to efavirenz (EFV). Here, we analyse data from an updated ART-CC database, to evaluate between-regimen differences in short-term virologic failure and rates of clinical events among treatment-na ve patients initiating ART between 2000 and 2005 conducting all analyses at the level of the individual regimen. We ï hypothesized that between-ART regimen differences in short-term virologic failure would not fully predict the effects on clinical endpoints.
METHODS

Cohorts
The Antiretroviral Therapy Cohort Collaboration (ART-CC) is a collaboration of 15 HIV cohort studies from Canada, Europe and the United States that was established in 2001. The collaboration has been described in detail elsewhere . Briefly, prospective cohort [23] [24] [25] [26] studies were eligible for participation if they had enrolled at least 100 HIV-1 infected patients aged 16 years who had: (1) not previously -≥ received antiretroviral treatment, (2) started ART with a combination of at least three antiretroviral drugs after 1996, and (3) been followed for a median duration of at least one year after ART initiation. (Canada) , and PISCIS, Catalonia and Balearic Islands (Spain) .
[40]
[41]
Data collection
Patient selection and data extraction were performed at the data centres of the participating cohorts. Anonymised data on a predefined set of demographic, laboratory, and clinical variables were pooled and analyzed centrally. Cohort data managers from EuroSIDA were asked to provide a unique study ID for each record as EuroSIDA patients may also be members of other cohort studies.
Statistical analyses
Analyses were restricted to HIV-1 positive subjects aged 16 years or older, who first started antiretroviral therapy in the period 1 January 2000 -31 December 2005 and had at least 6 months of potential follow-up before the cohort-specific database close date. Because of the focus on more recent ART regimens, study inclusion criteria required initiation of efavirenz (EFV), nevirapine (NVP), lopinavir/ritonavir (LPV/r), nelfinavir (NFV) or abacavir (ABC) as third drugs. We evaluated short-term (24-week) virologic failure " "
(HIV RNA >500 copies/mL) and longer-term clinical outcomes (incident AIDS-defining event, death from any cause, and a composite measure of these two outcomes) by third drug, in patients who were taking zidovudine and lamivudine (ZDV and 3TC) as the NRTI backbone. This approach was taken to focus on differences in virologic failure and clinical outcomes between third drugs given in combination with the same NRTI pair, such that potential differences in prescribing patterns for NRTI backbones across third drugs was not a factor. ZDV and 3TC were chosen as the NRTI backbone as this combination represented the most commonly prescribed NRTI pair (68 of regimens). All centres used the 1993 US Centers for Disease Control and Prevention criteria and guidelines for the definitive or % presumptive diagnosis of AIDS-defining events . Only new AIDS diagnosis, defined as the first occurrence of each AIDS-defining [42] condition was considered to be an incident event; recurrences of conditions were not considered. Change in regimen at six months after initiating ART was a secondary outcome.
To evaluate short-term virologic failure, logistic regression models were used to estimate crude and adjusted odds ratios (OR) of detectable 24-week plasma HIV-1 RNA, i.e. >500 copies/mL, among patients with an available measurement at that time ( / 3 month + − window). For this analysis, patients who died prior to 24 weeks and those with missing 24-week plasma HIV-1 RNA values were excluded. Logistic regression models were also used to estimate the crude and adjusted OR of not being on the initial regimen at 24 weeks, a secondary outcome measure. Sensitivity analyses were conducted evaluating 24-week virologic failure and initial ART regimen change for all patients, including those with missing 24-week measurements. For these analyses patients with missing 24-week plasma HIV RNA measures ( / 3 months), including those who died, were considered treatment failures ( missing equals failure ).
+ − " "
To evaluate clinical outcomes, we measured time from the date of initiating ART to earlier of the date that clinical endpoints occurred and the date of censoring (end of follow-up). In patients free of events, follow-up was censored on the date of the most recent visit plus half the usual visit interval (usually 3 months) for AIDS and the combined endpoint (incident AIDS event or death from any cause). For mortality, the censoring date was extended to the date the patient was last known to be alive in cohorts that could assert complete vital registration; otherwise, as above. Because the proportion of patients remaining on their initial regimen decreases over time, effects of initial regimen become increasingly diluted by regimen changes with increasing time since initiation of ART, Follow-up was therefore censored at 2 years after starting ART or at the cohort-specific close of database date, if either of these occurred sooner. Additional analyses, removing the 2-year censoring, were conducted to evaluate longer-term differences in clinical events according to initial ART regimen.
Weibull proportional hazards regression models were used to model the association of initial treatment regimen and other prognostic factors with disease progression as measured by clinical outcome measures. We estimated crude and adjusted hazard ratios (HR) comparing other third drugs with EFV when taken in combination with ZDV and 3TC. Analyses followed an intent to continue initial " therapy principle, in that eligible subjects were analyzed according to initial regimen, regardless of whether they later discontinued or " modified their therapeutic regimen.
All multivariable models were adjusted for age at initiation of therapy (16 29, 30 39, 40 49 >50 years), sex, transmission risk group 
RESULTS
Overall, 13,546 patients in the ART-CC initiated ART with the third drugs of interest (EFV, NVP, LPV/r, NFV, ABC) paired with ZDV and 3TC during the study period. Among study participants, 69 were male, 13 reported a history of IDU, and 20 had CDC % % % clinical stage C disease ( ). Overall, the median age (inter-quartile range) was 38 years (31 45), and the median CD4 count and Table 1 plasma log10 HIV RNA levels were 218 cells/ L (104 329) and 4.9 (4.4 5.3), respectively, at the time of ART initiation. During the μ --study period, EFV was the most commonly prescribed third drug (28 ), followed by LPV/r (21 ), ABC (19 ) , NFV (16 ) , and NVP (16
). Temporal trends in prescribing patterns measured as the proportion of overall ART prescriptions in a given year represented by each % antiretroviral drug indicated increased use of LPV/r and decreased use of all other third drugs over the course of the observation period (
). Compared with other third drugs, LPV/r was more commonly prescribed to patients with lower CD4 counts (median 150 cells/ Figure 1 μ L) and higher plasma HIV RNA levels (5.1 log 10 copies/mL), while the opposite was observed for ABC (median 251 cells/ L and 4.7 log μ 10 copies/mL) and NVP (median 260 cells/ L and 4.7 log 10 copies/mL) ( ).
μ Table 1 In multivariable logistic regression analyses among patients who had 24-week plasma HIV RNA measures (n 11,194, 83 ), = % detectable 24-week plasma HIV RNA (>500 copies/mL) was more common with all other third drugs than with EFV ( ). Findings Table 2 were most pronounced for NFV (adjusted with their initial regimen at 24 weeks than those receiving EFV ( ). Table 2 In general, sensitivity analyses including all patients (n 13,546) and utilising a missing equals failure approach gave similar results to
those observed in primary analyses, but with odds ratios that were attenuated towards one ( ). In these analyses the odds of Table 2a virologic failure were similar for LPV/r relative to EFV (adjusted OR 1.03, 95 CI 0.91, 1.16). This is in contrast to the primary analyses
in which the odds of 24-week virologic failure were higher with LPV/r compared with EFV. Sensitivity analyses of 24-week change of initial ART regimen yielded similar results to primary analyses, and parameter estimates were of comparable magnitude ( ). ). Because baseline CD4 counts tended to be higher for patients initiating NVP (median baseline CD4 count 260 cells/ L) than Table 3 μ those starting EFV (median 207 cells/ L), adjusted hazard ratios for this comparison were markedly greater than crude hazard ratios. In shows that by two years after starting ART there was an % = Table 3 Figure 2 estimated difference of about 2 in the cumulative probability of AIDS-free survival, between patients initiating ART on NFV and those the primary analyses, although confidence intervals were wider ( ). However, larger shifts in hazards ratios relative to primary Table 3a analyses were observed when AIDS events and death were modeled separately, relative to models of the composite clinical outcome measure. On the whole, sensitivity analyses of clinical outcomes restricted to non-IDU patients yielded similar findings to primary analyses ( ). Evaluation of longer-term clinical events by initial ART regimen removing 2 year censoring yielded similar results to Table 3b primary analyses although, as expected, hazard ratios were attenuated towards one ( ). Table 3c DISCUSSION Among antiretroviral-na ve patients initiating ART in clinical practice settings, short-term (24-week) virologic failure was more ï common for all third drugs evaluated (NVP, LPV/r, NFV, and ABC) relative to EFV when given in combination with ZDV and 3TC.
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While suppression of plasma HIV RNA is an important goal of treatment to avoid the emergence of viral resistance among other reasons, the ultimate aim of antiretroviral therapy is to prevent clinical progression and death. Preferred initial ART regimens change frequently, based on differential rates of virologic suppression observed in clinical trials. Our study suggests that such differences in virologic suppression between ART regimens may not translate to differences in clinical events among patients receiving treatment in a clinical practice setting. This observation may relate, in part, to the many available antiretroviral treatment options: patients failing treatment at 24-weeks may subsequently switch to other effective ART regimens. A recent study recognized the association of longitudinal CD4 count and plasma HIV RNA responses in contributing to long-term clinical outcomes in patients initiating modern ART, regardless of specific initial regimen .
[43]
Most previous observational studies (like RCTs) have lacked statistical power to analyze between-regimen differences in clinical events among patients initiating ART . The ART-CC makes such comparisons possible through the collaborative efforts of multiple [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] observational HIV cohort studies. The current study advances the findings of an earlier report from the ART-CC , by focusing on more [22] recent ART regimens at the level of the third drug among patients receiving the same NRTI backbone (ZDV and 3TC). Importantly, the current study allowed for the evaluation of LPV/r individually, and not grouped with other RTV-boosted protease inhibitors (amprenavir, saquinavir, and indinavir) as done in the earlier analysis due to the relatively small frequency of LPV/r use during the earlier evaluation period (1996 2002).
-
In contrast with our earlier study, in which RTV-boosted protease inhibitors were associated with increased rates of both short-term virologic failure and clinical outcomes compared with EFV , LPV/r was associated only with 24-week virologic failure in the current [22] study. The AIDS Clinical Trial Group (ACTG) 5142 study found a higher frequency of virologic failure among ARV-na ve patients ï treated with 2 NRTIs and LPV/r compared to those treated with 2 NRTIs and EFV . While EFV outperformed LPV/r in achieving [44] plasma HIV RNA levels <50 copies/mL and showed a trend for superiority at <200 copies/mL, increases in CD4 counts were greater for patients receiving LPV/r than for those receiving EFV in that randomized clinical trial. In the current study similar 24-week CD4 responses were observed for patients treated with LPV/r and EFV (median CD4 increase 110 cells/ L vs. 100 cells/ L, respectively). EFV-based regimens, although more virologically effective as shown in this study, may result in more HIV resistance upon failure making it more difficult to generate potent successive ART regimens. In contrast, it might be easier to find effective salvage regimens for patients failing an initial boosted-PI regimen due to the lower number of drug resistance mutations observed. Furthermore, another study found the emergence of resistance to NNRTIs was associated with a greater risk of subsequent death than was the emergence of PI resistance .
[46]
This updated analysis of the ART-CC found higher odds of 24-week virologic failure and hazards of clinical endpoints with NVP compared to EFV in analyses adjusted for covariates ( ). The findings regarding virologic failure are in contrast to the 2NN clinical Table 3 trial , but consistent with other observational studies comparing these NNRTIs . While we are not able to determine the reasons
[47] [18] [19] [20] for the observed inferior virologic and clinical outcomes associated with NVP use in the current study, it is possible that EFV outperformed NVP in a clinical practice setting. It is also possible that unmeasured confounders associated with NVP selection in clinical practice, confounding by indication, contributed to the inferior outcomes for NVP in the current study. Notably, shifts in parameter estimates for both NVP (increased) and LPV/r (decreased) for clinical outcome measures were observed between unadjusted and adjusted analyses attributable to differential patient profiles (e.g., baseline CD4 count and plasma HIV viral load) among patients stratified by third drug receipt ( ). Table 1 The impact of confounding by indication in the selection of third drugs was more apparent in the evaluation of clinical outcomes than observed in analyses of short-term virologic failure; more marked shifts in parameter estimates between crude and adjusted analyses were The findings of our study must be interpreted with regard to the study limitations. The potential for confounding is inherent to all observational studies. The impact of confounding by indication is demonstrated and discussed in this manuscript, but it is possible that other unmeasured confounders not included in adjusted statistical models may have contributed to observed study findings. As with prior studies of the ART-CC, we have adjusted for factors associated with clinical events (e.g., baseline CD4 count), but cannot rule out the possibility of unmeasured confounding. For example, it is possible that a provider s selection of initial ART regimen was influenced by ' their expectations of a patient s adherence to their antiretroviral medications. Such prescribing bias may represent unmeasured confounding ' that contributed to the between regimen differences in outcomes observed in this study. Furthermore, between-provider differences (e.g., experience) may also have contributed to differential outcomes. Finally, while the ART-CC has broad geographic representation from Europe and North America, findings of this study may not apply to other geographic settings.
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